Management of patients with neurofibromatosis type 1 and studies of pirfenidone

Research output: Contribution to journalArticle

Abstract

Aim: Neurofibromatosis type I (NF1) is a common tumour predisposing disease in humans. Plexiform neurofibromas are a major cause of morbidity in these patients. Unfortunately, effective medical therapy for these tumours is lacking. The histopathology of neurofibroma is complex, with diverse cellular content and large amount of fibrous tissue. We hypothesised that events connected with fibrogenesis might constitute a point of molecular vulnerability of plexiform neurofibromas. Methods: Pirfenidone is a novel, small molecule agent that exhibits potent activity against fibroblasts in vitro and in vivo. We developed an animal model for neurofibroma [human neurofibroma xenotransplants into severe combined immunodeficiency (SCID) mice] and evaluated effects of pirfenidone on neural tumour implants. Results: Survival of neurofibroma xenografts in SCID mice treated with oral pirfenidone was significantly lower when compared with survival of xenografts in non-treated animals. Based on encouraging preclinical studies, human studies for patients with plexiform neurofibromas have been initiated. Clinical trial on 24 adults was recently completed at Mayo Clinic and most patients remained stable for 2 years of treatment, not experiencing major toxicity. Paediatric phase I study has been completed and phase II study is still ongoing. Conclusion: Pirfenidone is a well-tolerated oral agent. Results from completed trials to date are promising, indicating its potential role in treatment of NF1. Because of the variable and incompletely understood natural history of neurofibromas, interpretation of outcome from clinical trials is difficult and will require longer follow-up of larger population of treated patients and placebo-controlled trials to determine the role of pirfenidone in the therapy of NF1-related tumours.

Original languageEnglish (US)
JournalPaediatrics and Child Health
Volume18
Issue numberSUPPL. 1
DOIs
StatePublished - Oct 1 2008

Fingerprint

Neurofibroma
Neurofibromatosis 1
Plexiform Neurofibroma
Severe Combined Immunodeficiency
Heterografts
Neoplasms
Clinical Trials
Therapeutics
Animal Models
Fibroblasts
Placebos
pirfenidone
Pediatrics
Morbidity
Survival
Population

Keywords

  • neurofibromatosis type I
  • pirfenidone
  • plexiform neurofibroma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Management of patients with neurofibromatosis type 1 and studies of pirfenidone. / Babovic-Vuksanovic, Dusica.

In: Paediatrics and Child Health, Vol. 18, No. SUPPL. 1, 01.10.2008.

Research output: Contribution to journalArticle

@article{eedc611e6731458cb5bcada2195f86b6,
title = "Management of patients with neurofibromatosis type 1 and studies of pirfenidone",
abstract = "Aim: Neurofibromatosis type I (NF1) is a common tumour predisposing disease in humans. Plexiform neurofibromas are a major cause of morbidity in these patients. Unfortunately, effective medical therapy for these tumours is lacking. The histopathology of neurofibroma is complex, with diverse cellular content and large amount of fibrous tissue. We hypothesised that events connected with fibrogenesis might constitute a point of molecular vulnerability of plexiform neurofibromas. Methods: Pirfenidone is a novel, small molecule agent that exhibits potent activity against fibroblasts in vitro and in vivo. We developed an animal model for neurofibroma [human neurofibroma xenotransplants into severe combined immunodeficiency (SCID) mice] and evaluated effects of pirfenidone on neural tumour implants. Results: Survival of neurofibroma xenografts in SCID mice treated with oral pirfenidone was significantly lower when compared with survival of xenografts in non-treated animals. Based on encouraging preclinical studies, human studies for patients with plexiform neurofibromas have been initiated. Clinical trial on 24 adults was recently completed at Mayo Clinic and most patients remained stable for 2 years of treatment, not experiencing major toxicity. Paediatric phase I study has been completed and phase II study is still ongoing. Conclusion: Pirfenidone is a well-tolerated oral agent. Results from completed trials to date are promising, indicating its potential role in treatment of NF1. Because of the variable and incompletely understood natural history of neurofibromas, interpretation of outcome from clinical trials is difficult and will require longer follow-up of larger population of treated patients and placebo-controlled trials to determine the role of pirfenidone in the therapy of NF1-related tumours.",
keywords = "neurofibromatosis type I, pirfenidone, plexiform neurofibroma",
author = "Dusica Babovic-Vuksanovic",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/S1751-7222(08)70016-7",
language = "English (US)",
volume = "18",
journal = "Paediatrics and Child Health (United Kingdom)",
issn = "1751-7222",
publisher = "Medicine Publishing",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Management of patients with neurofibromatosis type 1 and studies of pirfenidone

AU - Babovic-Vuksanovic, Dusica

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Aim: Neurofibromatosis type I (NF1) is a common tumour predisposing disease in humans. Plexiform neurofibromas are a major cause of morbidity in these patients. Unfortunately, effective medical therapy for these tumours is lacking. The histopathology of neurofibroma is complex, with diverse cellular content and large amount of fibrous tissue. We hypothesised that events connected with fibrogenesis might constitute a point of molecular vulnerability of plexiform neurofibromas. Methods: Pirfenidone is a novel, small molecule agent that exhibits potent activity against fibroblasts in vitro and in vivo. We developed an animal model for neurofibroma [human neurofibroma xenotransplants into severe combined immunodeficiency (SCID) mice] and evaluated effects of pirfenidone on neural tumour implants. Results: Survival of neurofibroma xenografts in SCID mice treated with oral pirfenidone was significantly lower when compared with survival of xenografts in non-treated animals. Based on encouraging preclinical studies, human studies for patients with plexiform neurofibromas have been initiated. Clinical trial on 24 adults was recently completed at Mayo Clinic and most patients remained stable for 2 years of treatment, not experiencing major toxicity. Paediatric phase I study has been completed and phase II study is still ongoing. Conclusion: Pirfenidone is a well-tolerated oral agent. Results from completed trials to date are promising, indicating its potential role in treatment of NF1. Because of the variable and incompletely understood natural history of neurofibromas, interpretation of outcome from clinical trials is difficult and will require longer follow-up of larger population of treated patients and placebo-controlled trials to determine the role of pirfenidone in the therapy of NF1-related tumours.

AB - Aim: Neurofibromatosis type I (NF1) is a common tumour predisposing disease in humans. Plexiform neurofibromas are a major cause of morbidity in these patients. Unfortunately, effective medical therapy for these tumours is lacking. The histopathology of neurofibroma is complex, with diverse cellular content and large amount of fibrous tissue. We hypothesised that events connected with fibrogenesis might constitute a point of molecular vulnerability of plexiform neurofibromas. Methods: Pirfenidone is a novel, small molecule agent that exhibits potent activity against fibroblasts in vitro and in vivo. We developed an animal model for neurofibroma [human neurofibroma xenotransplants into severe combined immunodeficiency (SCID) mice] and evaluated effects of pirfenidone on neural tumour implants. Results: Survival of neurofibroma xenografts in SCID mice treated with oral pirfenidone was significantly lower when compared with survival of xenografts in non-treated animals. Based on encouraging preclinical studies, human studies for patients with plexiform neurofibromas have been initiated. Clinical trial on 24 adults was recently completed at Mayo Clinic and most patients remained stable for 2 years of treatment, not experiencing major toxicity. Paediatric phase I study has been completed and phase II study is still ongoing. Conclusion: Pirfenidone is a well-tolerated oral agent. Results from completed trials to date are promising, indicating its potential role in treatment of NF1. Because of the variable and incompletely understood natural history of neurofibromas, interpretation of outcome from clinical trials is difficult and will require longer follow-up of larger population of treated patients and placebo-controlled trials to determine the role of pirfenidone in the therapy of NF1-related tumours.

KW - neurofibromatosis type I

KW - pirfenidone

KW - plexiform neurofibroma

UR - http://www.scopus.com/inward/record.url?scp=55049139332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55049139332&partnerID=8YFLogxK

U2 - 10.1016/S1751-7222(08)70016-7

DO - 10.1016/S1751-7222(08)70016-7

M3 - Article

AN - SCOPUS:55049139332

VL - 18

JO - Paediatrics and Child Health (United Kingdom)

JF - Paediatrics and Child Health (United Kingdom)

SN - 1751-7222

IS - SUPPL. 1

ER -